Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Merck
McKinsey
AstraZeneca
Boehringer Ingelheim

Last Updated: February 1, 2023

Details for Patent: 9,173,881


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 9,173,881 protect, and when does it expire?

Patent 9,173,881 protects UPTRAVI and is included in two NDAs.

This patent has forty-seven patent family members in twenty-eight countries.

Summary for Patent: 9,173,881
Title:Therapeutic compositions containing macitentan
Abstract: The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination of at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof. ##STR00001##
Inventor(s): Clozel; Martine (Binningen, CH)
Assignee: ACTELION PHARMACEUTICALS LTD. (Allschwil, CH)
Application Number:14/335,657
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 9,173,881

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Actelion UPTRAVI selexipag POWDER;INTRAVENOUS 214275-001 Jul 29, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN See Plans and Pricing
Actelion UPTRAVI selexipag TABLET;ORAL 207947-001 Dec 21, 2015 RX Yes No See Plans and Pricing See Plans and Pricing METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN See Plans and Pricing
Actelion UPTRAVI selexipag TABLET;ORAL 207947-002 Dec 21, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN See Plans and Pricing
Actelion UPTRAVI selexipag TABLET;ORAL 207947-003 Dec 21, 2015 RX Yes No See Plans and Pricing See Plans and Pricing METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN See Plans and Pricing
Actelion UPTRAVI selexipag TABLET;ORAL 207947-004 Dec 21, 2015 RX Yes No See Plans and Pricing See Plans and Pricing METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN See Plans and Pricing
Actelion UPTRAVI selexipag TABLET;ORAL 207947-005 Dec 21, 2015 RX Yes No See Plans and Pricing See Plans and Pricing METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,173,881

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/IB2008/053252Aug 13, 2008

International Family Members for US Patent 9,173,881

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 073031 See Plans and Pricing
Australia 2009280843 See Plans and Pricing
Brazil PI0917661 See Plans and Pricing
Canada 2731370 See Plans and Pricing
China 102099026 See Plans and Pricing
Cyprus 1119826 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
McKesson
McKinsey
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.